A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Nutritional Supplement Lumenato and Its Impact on Skin Parameters in Healthy Female Subjects

Inclusion criteria: * Resides in the United States * Generally healthy women between the ages of 35-55 * Fitzpatrick skin types 2 or 3 * Identifies as one of the following: White, Hispanic/Latino, or both White and Hispanic/Latino * Type 2 on the Glogau Skin Classification scale * Has expressed interest in improving skin health and appearance * Willing and able to follow the procedures of the study * Willing to refrain from changing their diet or lifestyle significantly for the duration of the study * Able to understand the study requirements and activities in English, and provide informed consent * Access to reliable internet service and smartphone in order to utilize the ClaimIt software/app needed to remotely participate in the study Exclusion Criteria: * Participants with Fitzpatrick skin types of 1, 4, 5 or 6 * Known allergies or sensitivity to tomato, latex and/or potato * Current use or use within 1 month of study enrollment of hormonal therapies (including hormonal contraceptives) * Current, regular use or regular use within 1 month of study enrollment of oral steroids; regular use defined as \>10 consecutive days * Chronic or relapsing inflammatory and/or allergic skin conditions such as atopic dermatitis, rosacea, psoriasis and alike including telangiectasias ("spider veins") * Pregnant, lactating or breastfeeding women (within the last 6 months) or those planning to become pregnant during the study period * Less than 2 years since diagnosis or treatment of skin cancer including basal cell carcinoma, squamous cell carcinoma, melanoma- excluding actinic keratosis * Currently active herpes infections or currently on treatment for herpes infections * History of facial keloids * Current diagnosis of adult acne or currently on treatment for adult acne * Recent (\<6 months at enrollment) cardiovascular conditions such as stroke, transient ischemic attack (TIA), or myocardial ischemia/infarction, recently on treatment for congestive heart failure, or currently having vasculitis or vascular conditions * On potent blood thinners such as low-molecular weight heparin (LMWH), rivaroxaban, apixaban, or other prescription blood thinners - excludes aspirin * Holds a current diagnosis of diabetes mellitus type I or II * Participants who have received facial irradiation within last year or are planning on undergoing facial irradiation during the study * Chronic liver disease- excluding early stage non-alcoholic fatty liver disease (NAFLD) * Chronic kidney disease or recent (\<6 months at enrollment) acute kidney disease * Participants who currently take supplements containing carotenoids, lutein, melatonin or tryptophan * Participants with occupations or lifestyle that require significant daily exposure to the sun (defined as at least 1 hour of continuous outdoor sun exposure) * Participants who have had a sunburn in the last 2 weeks * Participants who use tanning salons or tanning products in the last 3 months * Participants who plan to undergo invasive facial procedures (injections, chemical peeling, etc.) during the study or have undergone these procedures within 2 months prior to enrollment * Change in oral supplements or medications targeting skin health within 2 months prior to enrollment * Participants who are HIV positive * Participants who are immunosuppressed * Participants with a recent (\<2 months prior to enrollment) diagnosis of a psychiatric condition * Participants having chronic connective tissue disorder affecting the skin (e.g. Ehlers- Danlos syndrome, Marfan's Syndrome, Osteogenesis Imperfecta) * Participants with auto-immune skin diseases (e.g. scleroderma, psoriasis, lupus, epidermolysis bullosa, bullous pemphigoid, temporal arteritis) * Participants who have been prescribed retinoids treatment (\<2 months prior to enrollment) * Participants who meet either/or both of the following criteria with regards to smoking habits (smoking includes cigarettes, e-cigs, pipes, hookah, cigars): * Who are current smokers (smoked at least 100 cigarettes, or tobacco/nicotine equivalent, in her lifetime) and who continue to use these products * Who were former smokers (smoked at least 100 cigarettes, or tobacco/nicotine equivalent, in her lifetime, but who have quit smoking) who have smoked within the last year and/or were former smokers for 10 years * Participants who drink more than 14 drinks per week (more than 2 drinks per night) * Participants who use illicit or illegal drugs * Participants who are regular users of cannabis substances or substances derived from cannabis such as CBD, CBD oils or balms, cannabis-containing edibles; vaping; smoking; hookahs. * NOTE: regular use is defined as long stretches of inhaling or consuming these products over several months or longer. Occasional, but not weekly, use of products with small amounts of CBD-related compounds (e.g. waters with CBD infusions) are not considered regular use.) * Participants who are planning a trip to the mountains or to a higher UV index region during the study period * Any other medication, condition or disease that in the PI's opinion that may adversely affect the participant's ability to complete the study, substantially impact the study's integrity or may pose a significant risk to the participant * Participants who are experiencing perimenopausal or menopausal symptoms * Participants who have had a hysterectomy and/or both of their ovaries removed